He is also the Principal Investigator of the Translational Geroscience Network (R33 AG061456), which brings together 8 academic institutions to translate healthspan interventions, including senolytics and other drugs that target fundamental aging processes. He is a board-certified specialist in internal medicine, geriatrics, endocrinology and metabolism.
James published the first clinical trials of senolytic drugs, and throughout his research, he demonstrated that senolytic agents enhance health span and delay, prevent, or alleviate multiple age-related disorders and diseases in mouse models. He is currently conducting multiple clinical trials of senolytics, including three clinical trials for COVID-19.
James has previously held positions at the National Advisory Council on Aging of the National Institutes of Health and at the Clinical Trials Advisory Panel of the National Institute on Aging. He was also a Chair Member of the Biological Sciences Section of the Gerontological Society of America.
James Kirkland has more than 225 publications and holds over 20 patents. In 2020, American Federation for Aging Research awarded him with the Irving S. Wright Award of Distinction.